2020 John N. Insall Award: Removal of total knee arthroplasty from the inpatient-only list adversely affects bundled payment programmes

• Published in: Journal of bone and joint surgery. British volume Vol. 102-B; no. 6; pp. 19 - 23
• Main Authors: Yayac, Michael, Schiller, Nicholas, Austin, Matthew S, P Maxwell Courtney
• Format: Journal Article
• Language: English
• Published: London British Editorial Society of Bone & Joint Surgery 01-06-2020
• Subjects: Cost control; Joint replacement surgery; Joint surgery; Medicare
• ISSN: 2049-4394; 2049-4408
• DOI: 10.1302/0301-620X.102B6.BJJ-2019-1369

AimsThe purpose of this study was to determine the impact of the removal of total knee arthroplasty (TKA) from the Medicare Inpatient Only (IPO) list on our Bundled Payments for Care Improvement (BPCI) Initiative in 2018.MethodsWe examined our institutional database to identify all Medicare patients who underwent primary TKA from 2017 to 2018. Hospital inpatient or outpatient status was cross-referenced with Centers for Medicare & Medicaid Services (CMS) claims data. Demographics, comorbidities, and outcomes were compared between patients classified as ‘outpatient’ and ‘inpatient’ TKA. Episode-of-care BPCI costs were then compared from 2017 to 2018.ResultsOf the 2,135 primary TKA patients in 2018, 908 (43%) were classified as an outpatient and were excluded from BPCI. Inpatient classified patients had longer mean length of stay (1.9 (SD 1.4) vs 1.4 (SD 1.7) days, p < 0.001) and higher rates of discharge to rehabilitation (17% vs 3%, p < 0.001). Post-acute care costs increased when comparing the BPCI patients from 2017 to 2018, ($5,037 (SD $7,792) vs $5793 (SD $8,311), p = 0.010). The removal of TKA from the IPO list turned a net savings of $53,805 in 2017 into a loss of $219,747 in 2018 for our BPCI programme.ConclusionsFollowing the removal of TKA from the IPO list, nearly half of the patients at our institution were inappropriately classified as an outpatient. Our target price was increased and our institution realized a substantial loss in 2018 BPCI despite strong quality metrics. CMS should address its negative implications on bundled payment programmes.Cite this article: Bone Joint J 2020;102-B(6 Supple A):19–23.